Full Press Release Details
CRANFORD, N.J. , Sept. 6, 2023 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR ), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced its participation in two investor conferences in September 2023 . Citius Chairman and CEO Leonard Mazur will present at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023 , and at the Sidoti Small-Cap Virtual Conference on Wednesday, September 20, 2023 .
H.C. Wainwright Conference Details:
Presentation:
2:00 pm ET on September 11, 2023
Location:
Lotte New York Palace Hotel, New York City
R egistration:
A vailable on the conference website .
1x1 meetings:
Requests available upon registration or by contacting Citius Investor Relations .
Webcast:
Join live .
Sidoti Conference Details:
Presentation:
2:30 pm ET on September 20, 2023
Location:
Virtual
R egistration:
A vailable on the conference website .
1x1 meetings:
Requests available through a Sidoti representative.
About Citius Pharmaceuticals, Inc.
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company's diversified pipeline includes two late-stage product candidates, Mino-Lok ® , an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections, which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in CTCL. Mino-Lok was granted Fast Track designation by the FDA. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. At the end of March 2023 , Citius completed enrollment in its Phase 2b trial of CITI-002, a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com .